ABN 201
Alternative Names: ABN-201Latest Information Update: 06 Aug 2024
Price :
$50 *
At a glance
- Originator Abion
- Class Antibodies; Antineoplastics; Cytokines; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 06 Aug 2024 Preclinical development is ongoing in South Korea (Abion pipeline, August 2024)
- 06 Aug 2024 Preclinical trials in Solid tumours in South Korea (Parenteral) before August 2024 (Abion pipeline, August 2024)
- 28 Sep 2023 No recent reports of development identified for research development in Solid-tumours in South Korea (Parenteral)